Jun 2026 (Q2 FY26) — Aug 12, 2026
Longeveron Q2 FY26 — HLHS Data Readout Expected Mid-September, XPRIZE Finalist
Read the full callLongeveron (LGVN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Longeveron earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.29 | −9.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -2150.2 | −442.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -6.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.39 0.00% · $0
Performance −82.1% 1Y
1Y: $7.78 on 17 Oct 2025 → $1.39. High $11.6 (7 Apr 2026), low $1.39 (16 Oct 2026).
- Previous close
- $1.39
- 52-week range
- $1.39 – $11.6
- One year
- −82.75%
Overview
- Symbol
- LGVN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Longeveron earnings calls (LGVN)
Financials
What the filings say
Net profit, year on year: −21% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | -5 | -4 | -5 | -5 | -7 | -5 | -5 | -6 |
| Operating margin | −601.4% | −710.3% | −1359.8% | −1707.9% | −5335.8% | −1479.2% | −1199.8% | −2150.2% |
| Other income | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Net profit | -4 | -4 | -5 | -5 | -7 | -5 | -5 | -6 |
| EPS ($ per share) | -0.34 | — | -0.34 | -0.33 | -0.39 | — | -0.19 | -0.19 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | — | — | — |
| Reserves | — | -44 | -63 | -85 | -110 | -132 |
| Total liabilities | 7 | 5 | 7 | 5 | 4 | 5 |
| Fixed assets | 4 | 3 | 3 | 3 | 2 | 2 |
| Investments | — | 9 | 9 | 0 | 0 | — |
| Total assets | 9 | 43 | 27 | 12 | 26 | 10 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -2 | -10 | -14 | -19 | -14 | -19 |
| Cash from investing | -0 | -11 | -1 | 8 | -1 | -1 |
| Cash from financing | 2 | 45 | -1 | 5 | 29 | 5 |
| Capital expenditure | -0 | -0 | -1 | -0 | -1 | -0 |
| Free cash flow | -2 | -10 | -15 | -19 | -15 | -19 |
Insider filings
41 filings between Jan 2, 2026 and Oct 1, 2026.
Open market
decisions to buy or sellNobody bought or sold LGVN on the open market in this window. The filings below are 20 awards and 21 tax withholdings.
Compensation
not trading decisions- 20
- Award — granted as compensation
- 21
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Agafonova Nataliya Chief Medical Officer | Tax withheld | 2,913 | $7.5K |
| Oct 1, 2026 | Lehr Paul T General Counsel, Secretary | Tax withheld | 2,253 | $5.8K |
| Oct 1, 2026 | Willard Stephen H Chief Executive Officer | Tax withheld | 1,987 | $5.1K |
| Oct 1, 2026 | Jhaveri Nirav S. Chief Financial Officer | Tax withheld | 742 | $1.9K |
| Oct 1, 2026 | Blass Devin CTO & SVP of CMC | Tax withheld | 2,520 | $6.5K |
| Aug 19, 2026 | Soffer Rock Director | Award | 36,000 | $0 |
| Aug 19, 2026 | Hajjar Roger Joseph Director | Award | 36,000 | $0 |
| Aug 19, 2026 | Lehr Paul T General Counsel, Secretary | Award | 286,000 | $0 |
| Aug 19, 2026 | Paletta George A. Jr. Director | Award | 36,000 | $0 |
| Aug 19, 2026 | Cann Leah Rush Director | Award | 36,000 | $0 |
| Aug 19, 2026 | Hare Joshua Chief Scientific Officer | Award | 286,000 | $0 |
| Aug 19, 2026 | Agafonova Nataliya Chief Medical Officer | Award | 286,000 | $0 |
| Aug 19, 2026 | Blass Devin CTO & SVP of CMC | Award | 286,000 | $0 |
| Aug 19, 2026 | Ascheim Deborah Director | Award | 36,000 | $0 |
| Aug 19, 2026 | Desai Arjun JJ Director | Award | 36,000 | $0 |
| Aug 19, 2026 | Ungaro Ursula Director | Award | 36,000 | $0 |
| Aug 17, 2026 | Jhaveri Nirav S. Chief Financial Officer | Award | 300,000 | $0 |
| Jul 6, 2026 | Hare Joshua Chief Scientific Officer | Award | 600,000 | $0 |
| Jul 1, 2026 | Blass Devin CTO & SVP of CMC | Tax withheld | 15,808 | $11.5K |
| Jul 1, 2026 | Agafonova Nataliya Chief Medical Officer | Tax withheld | 22,505 | $16.4K |
| Jul 1, 2026 | Locklear Lisa Chief Financial Officer | Tax withheld | 22,505 | $16.4K |
| Jul 1, 2026 | Willard Stephen H Chief Executive Officer | Tax withheld | 18,046 | $13.2K |
| Jul 1, 2026 | Lehr Paul T General Counsel, Secretary | Tax withheld | 13,143 | $9.6K |
| May 1, 2026 | Agafonova Nataliya Chief Medical Officer | Award | 250,000 | $0 |
| May 1, 2026 | Locklear Lisa Chief Financial Officer | Award | 250,000 | $0 |
| May 1, 2026 | Blass Devin CTO & SVP of CMC | Award | 250,000 | $0 |
| May 1, 2026 | Willard Stephen H Chief Executive Officer | Award | 500,000 | $0 |
| May 1, 2026 | Lehr Paul T General Counsel, Secretary | Award | 250,000 | $0 |
| Apr 1, 2026 | Blass Devin CTO & SVP of CMC | Tax withheld | 8,633 | $9.7K |
| Apr 1, 2026 | Willard Stephen H Chief Executive Officer | Tax withheld | 4,740 | $5.3K |
| Apr 1, 2026 | Locklear Lisa Chief Financial Officer | Tax withheld | 13,145 | $14.7K |
| Apr 1, 2026 | Agafonova Nataliya Chief Medical Officer | Tax withheld | 13,145 | $14.7K |
| Apr 1, 2026 | Lehr Paul T General Counsel, Secretary | Tax withheld | 5,611 | $6.3K |
| Mar 2, 2026 | Willard Stephen H Chief Executive Officer | Award | 200,000 | $0 |
| Mar 2, 2026 | Willard Stephen H Chief Executive Officer | Tax withheld | 105,533 | $57.5K |
| Mar 2, 2026 | Willard Stephen H Chief Executive Officer | Award | 200,000 | $0 |
| Jan 2, 2026 | Locklear Lisa Chief Financial Officer | Tax withheld | 10,250 | $6.1K |
| Jan 2, 2026 | Lehr Paul T General Counsel, Secretary | Tax withheld | 6,952 | $4.1K |
| Jan 2, 2026 | Agafonova Nataliya Chief Medical Officer | Tax withheld | 10,250 | $6.1K |
| Jan 2, 2026 | Blass Devin CTO & SVP of CMC | Tax withheld | 10,700 | $6.3K |
| Jan 2, 2026 | Powell James Nathaniel Chief Executive Officer | Tax withheld | 2,464 | $1.5K |
| Oct 1, 2025 | Paletta George A. Jr. Director | Award | 34,000 | $0 |
| Oct 1, 2025 | Agafonova Nataliya Chief Medical Officer | Tax withheld | 11,883 | $8.8K |
| Oct 1, 2025 | Locklear Lisa Chief Financial Officer | Tax withheld | 11,883 | $8.8K |
| Oct 1, 2025 | Blass Devin CTO & SVP of CMC | Tax withheld | 7,609 | $5.6K |
| Oct 1, 2025 | Lehr Paul T General Counsel, Secretary | Tax withheld | 4,944 | $3.7K |
| Oct 1, 2025 | Powell James Nathaniel Chief Executive Officer | Tax withheld | 2,389 | $1.8K |
| Sep 4, 2025 | Powell James Nathaniel Chief Executive Officer | Award | 50,000 | $0 |
| Aug 11, 2025 | Baluch Khoso Director | Purchase | 11,766 | — |
| Aug 11, 2025 | Locklear Lisa Chief Financial Officer | Purchase | 11,766 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Longeveron Inc.
Free account. Everything above stays public.
Write why you follow Longeveron Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading